H.C. Wainwright lowered the firm’s price target on Astria Therapeutics to $16 from $18 and keeps a Buy rating on the shares. The analyst says data for STAR-0215 from the ALPHA-STAR study “significantly de-risk” the program for the upcoming pivotal study. The thesis is “strong as catalysts a bit off in future with game changing data,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics Expands Board, Appoints New Director
- Astria Therapeutics appoints Agarwal to board of directors
- Astria Therapeutics price target raised to $22 from $17 at Wedbush
- Spyre Therapeutics price target raised to $54 from $36 at Stifel
- Astria: ‘Positive’ initial proof-of-concept results from STAR-0215 for HAE trial
